Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed and produced BBM-D101 injection for Duchenne Muscular Dystrophy (DMD) has successfully completed the first patient dosing in Beijing, China.

Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy

#dmd #duchenne #BBMD101 #BeliefBioMed #clinicaltrials

👉 Read More: DMDWarrioR.com

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101 The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for Belief BioMed’s (BBM) Duchenne Muscular Dystrophy (DMD) gene therapy candidate, BBM-D101. BBM is a forward-thinking biotechnology company that focuses on creating innovative gene therapies.

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #gene #dna #beliefbiomed #BBMD101 #china #shanghai